Redeye: XVIVO Perfusion - Strong growth and operational leverage
XVIVO Q4 is another solid quarter with 44% organic growth (CER), 6-7% above expectations. The main growth driver is disposables, where Thoracic, XVIVO’s most prominent business unit, delivered 50% organic growth and improved disposables gross margins to 87%. XVIVO continues to invest in sustainable growth during 2025 ahead of substantial launch support.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/